Antisense Therapeutics is an Australian publicly-listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ: IONS), an established leader in antisense drug development.

The Company is developing ATL1102, an antisense inhibitor of the CD49d receptor, for Duchenne Muscular Dystrophy (DMD) patients and recently reported highly promising Phase II trial results.  ATL1102 has also successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS). The Company has a second drug, ATL1103 designed to block GHr production that successfully reduced blood IGF-I levels in Phase II clinical trials in patients with the growth disorder acromegaly.

Latest News

Antisense Therapeutics and Murdoch Children’s Research Institute enter into new R&D collaboration to further explore ATL1102 use in multiple muscle diseases

ATL1102 for DMD EMA PIP feedback and FDA regulatory progress

US FDA Feedback on Type C Meeting for ATL1102 in the US

Manufacture of ATL1102 clinical supplies for Phase IIb trial in DMD